LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

CureVac NV

Cerrado

5.38 -0.19

Resumen

Variación precio

24h

Actual

Mínimo

5.33

Máximo

5.4

Métricas clave

By Trading Economics

Ingresos

-409M

-39M

Ventas

-479M

14M

P/B

Media del Sector

5.864

50.291

BPA

-0.156

Margen de beneficio

-266.508

Empleados

825

EBITDA

-410M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-23.35% downside

Dividendos

By Dow Jones

Próximas Ganancias

14 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

478M

1.2B

Apertura anterior

5.57

Cierre anterior

5.38

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

CureVac NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 jul 2024, 09:14 UTC

Adquisiciones, fusiones, absorciones

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

12 jun 2025, 14:20 UTC

Adquisiciones, fusiones, absorciones

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 jun 2025, 13:34 UTC

Acciones populares

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 jul 2024, 09:38 UTC

Charlas de Mercado

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Comparación entre iguales

Cambio de precio

CureVac NV Esperado

Precio Objetivo

By TipRanks

-23.35% caída

Estimación a 12 meses

Media 4.17 USD  -23.35%

Máximo 5.5 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CureVac NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

3.47 / 3.755Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.